Cryptosporidiosis in newborn calves in Ankara region: clinical, haematological findings and treatment with Lasalocid-Na

WOS: 000231365600001PubMed: 16028484In the first part of the present study, a total of 109 faeces samples collected from calves suffering from diarrhoea were examined for Cryptosporidium parvum oocytes and 39 (35,8 %) of them were found to be positive. On the basis of oocyte counts, 14 (36 %) samples were assessed as mildly infected and 25 (64 %) samples as heavily infected. The occurrence of the disease was more common in winter (56,4 %) than during other seasons (autumn 0 %, summer 15,4 %, spring 28,2 %). In the second part of the present study, the ionophore polyetherantibiotic Lasalocid-Na, that is licensed as a feed additive (Bovatec (R), 15 % Lasalocid-Na, Roche AG) in Turkey, was administered to 11 calves naturally infected with Cryptosporidium and its therapeutic effect was evaluated. Lasalocid-Na (8 mg/ kg BW) was given once daily for 3 days added to the milk. The clinical parameters of infected calves were evaluated before and 3 days after the treatment in 24 hour intervals. The oocyst counts of faeces of calves with cryptosporidiosis were between 15 x 10(6) and 96 x 10(6)/mL before treatment. No oocystes were found in faecal samples of 3 calves (27,3 %) after 48 hours and 4 (40 %) calves after 72 hours of treatment, respectively. The number of oocytes in the faeces of the remaining calves varied between 90 and 1,2 x 106/mL during the respective period. The number of oocystes before treatment was significantly higher than the number of oocytes after treatment. One of the calves died 56 h after the first treatment despite the treatment. The pH of venous blood was decreased prior to treatment as expected. The lowest pH was 6,83, the lowest bicarbonate concentration was 3,80 mmol/l and the lowest base excess was -31,2 mmol/l. After the treatment, pH, pCO(2), HCO3- and BE values of the venous blood increased significantly and reached physiological values before discharge. The differences between the values assessed before the treatment and at the 2(nd), 3(rd), and 4(th) sampling time were statistically significant. Number of leucocyte and haemoglobin concentration before the treatment were significantly higher than the values after treatment (p < 0,01). These values returned back to physiological ranges 72 hours after first treatment. Lasalocid-Na was rather well tolerated. Side effects such as the decline of the suckling reflex and intoxication symptoms in respect to present administration form and dosage were found only in one calf (9 %). Treatment procedure in the present study with Lasalocid-Na was found to be suitable in combination with an adequate infusion therapy for the treatment of calves on farms with problems related to cryptosporidiosis. Although the use of Lasolacid-Na for the treatment of Cryptosporidium infection in the EU is banned, it might be used as an alternative drug outside of the EU since it has a successful effect for preventing reinfections

Species distribution, antifungal susceptibility and clonal relatedness of Candida isolates from patients in neonatal and pediatric intensive care units at a medical center in Turkey

The aim of this study was to assess species distribution, antifungal susceptibility and clonal relationships among Candida strains isolated from a group of pediatric/neonatal intensive care (PICU/NICU) patients that had a very high mortality rate (76%). The cases of 21 patients (19 with candidemia, 2 with Candida meningitides) treated over a 1-year period in a Turkish hospital PICU and NICU were retrospectively analyzed. Twenty-eight Candida isolates were detected from blood (20), cerebrospinal fluid (CSF) (2) and other specimens (6). Candida species were identified using the API ID 32C System. Susceptibility testing was done (all 28 isolates) for amphotericin B, fluconazole and itraconazole using the broth microdilution method. Arbitrarily primed polymerase chain reaction (AP-PCR) was used for molecular typing of the 3 most common ones; C. albicans (15), C. parapsilosis (6), and C. pelliculosa (4). Electrophoretic karyotyping (EK) was done to check clonal identity obtained by AP-PCR. Of the 20 blood isolates, 8 (40%) were C. albicans, 12 (60%) were non-albicans Candida, and one of the 2 CSF isolates was C. albicans. The overall species distribution was as follows: 15 C. albicans isolates, 6 C. parapsilosis isolates, 4 C. pelliculosa isolates, 2 C. famata isolates and 1 C. tropicalis isolate. Amphotericin B had the best antifungal activity with a MIC90 of 0.125 µg/ml, and the rates of susceptibility to fluconazole and itraconazole were 93% and 82%, respectively. AP-PCR revealed 11 genotypes (4 were identical pairs, 7 were distinct) among the 15 C. albicans isolates, 2 genotypes (5 were classified in the same type) among the 6 C. parapsilosis isolates, and 4 separate genotypes for the 4 C. pelliculosa isolates. Karyotyping results correlated well with the AP-PCR findings. As indicated in the previous research, our results confirmed that non-albicans Candida species have become more frequently causative agents for invasive fungal infections in the ICU. Transmission of C. albicans and C. pelliculosa was relatively low, but transmission of C. parapsilosis was high, suggesting that more effective control and very strict treatment protocols are needed for patients having high mortality and invasive fungal infection in ICU